Clinical Trial Update: Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial [Phase 2]

View source ↗

Summary

A Phase 2 trial investigates discontinuing dasatinib in patients with chronic myeloid leukemia in chronic phase who have maintained complete molecular remission…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Shimousa Hematology Study Group | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: UNKNOWN